Impact of the loss of Laboratory Developed Mass Spectrometry testing at a major academic medical center.

导出 LinkOut

翻译打印收藏纠错

第一作者： K Aaron,Geno

第一单位： Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.

作者： K Aaron,Geno ^[1] ; Mark A,Cervinski ^[2]

作者单位： Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. ^[1] The Geisel School of Medicine at Dartmouth, Hanover, NH, USA. ^[2]

关键词 CLIA CLIA, clinical laboratory improvement amendments Cyclo A, cyclosporine A EUA, emergency use authorization FDA FDA, food and drug administration ISD, immunosuppressant drug monitoring IVD, In-vitro diagnostic LCMS, liquid chromatography mass spectrometry LDT LDT, laboratory developed test Laboratory developed test MS, mass spectrometry TAT, turnaround time TDM, therapeutic drug monitoring VALID Act VALID, verifying accurate leading-edge IVCT development

DOI 10.1016/j.jmsacl.2023.02.005

PMID 36846026

发布时间 2023-03-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Journal of mass spectrometry and advances in the clinical lab

2023年28卷

63-66页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Impact of the loss of Laboratory Developed Mass Spectrometry testing at a major academic medical center.

Journal of mass spectrometry and advances in the clinical lab

相似文献

Journal of mass spectrometry and advances in the clinical lab

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Impact of the loss of Laboratory Developed Mass Spectrometry testing at a major academic medical center.

Journal of mass spectrometry and advances in the clinical lab

相似文献

Journal of mass spectrometry and advances in the clinical lab

相关期刊

检索历史清除